Item request has been placed!
×
Item request cannot be made.
×
Processing Request
ImmunoGen, Inc. Initiates Phase I Trial of IMGN853 in Ovarian Cancer and Other Solid Tumors Over-Expressing Its Folate Receptor Target.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- معلومة اضافية
- الموضوع:
- نبذة مختصرة :
The article offers information on the initiation of phase one clinical trial by ImmunoGen Inc. to demonstrate the safety, tolerability, and pharmacokinetics of new drug, IMGN853 in treatment of ovarian cancer and other solid tumors associated with overexpression of folate receptor alpha, FOLR1. 64 ovarian cancer patients will be enrolled for the study.
No Comments.